Active Surveillance: Prostate Cancer VL - Results from #10

Active Surveillance: Prostate Cancer VL

Search

AI-Powered Prostate Cancer Grading Predicts Active Surveillance Outcomes - Cornelia Ding Details Andrea Miyahira interviews Cornelia (Chien-Kuang) Ding about her study on predicting prostate cancer grade reclassification using a deep learning-based grading algorithm. Dr. Ding discusses their evaluation of the AIRAProstate algorithm across two cohorts at Johns Hopkins University. The study reveals that AI-based upgrading of initial biopsies is associated with later grade reclassification in ac...
Exploring Financial Toxicity and Cultural Differences in Prostate Cancer Active Surveillance "Discussion" Details At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts discuss several key issues in prostate cancer management and nomenclature. The group raises questions about the financial toxicity of active surveillance, particularly for underserved populations, and whether high-quality access to care could improve surveillance outcomes. They also consi...
MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression - Neil Fleshner Details Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin's potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing canc...
2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
MAST Trial: Investigating Metformin's Role in Prostate Cancer Active Surveillance - Anthony Joshua Details Anthony Joshua presents the findings of the MAST trial, a decade-long investigation into the use of metformin for men with low-risk prostate cancer under active surveillance. Conducted across 12 Canadian centers, this randomized Phase III study involved 408 men and aimed to determine if metformin could delay cancer progression. Despite earlier promising studies suggesting potential benefits, the t...